Last updated on May 2018

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis X) in Patients With Dry Eye Disease


Brief description of study

This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will participate in Stage 2 of this study.

Clinical Study Identifier: NCT02013791

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Registry Team

Sall Research Medical Center
Artesia, CA United States

Clinical Trials Registry Team

Lugene Eye Institute
Glendale, CA United States

Clinical Trials Registry Team

Lakeside Vision Center
Irvine, CA United States

Clinical Trials Registry Team

Dr. Nanduri's Associated Eye Surgeons Medical Group/Envision Eye
La Jolla, CA United States

Clinical Trials Registry Team

Scripps Clinic
La Jolla, CA United States

Clinical Trials Registry Team

M.D. Med Associates
Newport Beach, CA United States

Clinical Trials Registry Team

Wolstan & Goldberg Eye Associates
Torrance, CA United States

Clinical Trials Registry Team

Vision Institute
Colorado Springs, CO United States

Clinical Trials Registry Team

Johns Hopkins University - Wilmer Eye Institute
Baltimore, MD United States

Clinical Trials Registry Team

Abrams Eye Institute
Las Vegas, NV United States

Clinical Trials Registry Team

Eye Centers of Racine and Kenosha
Kenosha, WI United States